Cerebrospinal fluid proteomics exerts predictive potential for immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T cell therapy
Open Access
- 11 March 2025
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 39 (4) , 983-987
Abstract
No abstract availableKeywords
Funding Information
- MEXT | Japan Society for the Promotion of Science (21H02950)
This publication has 17 references indexed in Scilit:
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialThe Lancet, 2022
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaNew England Journal of Medicine, 2022
- Cytokine release syndrome and associated neurotoxicity in cancer immunotherapyNature Reviews Immunology, 2021
- Side-effect management of chimeric antigen receptor (CAR) T-cell therapyAnnals of Oncology, 2021
- Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomasNature Medicine, 2020
- Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomesNeuro-Oncology, 2020
- Clinical promise of next-generation complement therapeuticsNature Reviews Drug Discovery, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2019
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen ReceptorJournal of Immunotherapy, 2009